Nuclear medicine company Curium has signed a long-term agreement to extend its current partnership with NRG Pallas for new irradiation services at Petten, the Netherlands, to produce non-carrier added lutetium-177 (Lu-177).

Curium, which has manufacturing facilities across Europe and the US, said in a statement that the extension of the partnership will strengthen its plans to benefit more than 100,000 critically ill patients worldwide over the next five years.

The Lu-177 will be produced using the High-Flux Reactor (HFR) at the NRG Pallas site in Petten. The HFR has been a pillar of the world’s patient access to molybdenum-99 (Mo-99) over the past 40-plus years, and more recently for Lu-177, Curium said.